Bioton buys rights

The transaction guarantees Bioton unlimited rights to produce and sell such insulin without additional charges, thanks to which the company plans to save millions of złoty on license fees. Bioton's president, Adam Wilczęga, says that the deal will enable the concern to enter new markets, including Western Europe and the US.